Immunotherapy play eTheRNA raises EUR 24M

eTheRNA N.V. (Brussels, Belgium) raised EUR 24 million ($26.7 million) in a series A round led by LSP Life Sciences Partners and PMV. Other investors included Omega Funds, Fund+ and Boehringer Ingelheim Venture Fund.

eTheRNA, a spinout from Vrije Universiteit Brussel (VUB), is developing therapies based on its TriMix technology, which involves mixing three mRNA molecules that the company said are "jointly capable of both activating and educating dendritic cells." ...